Biotech company Immunai, which developed an AI-based immune system mapping technology for drug development, announces the ...

Mikael Dolsten, M.D., Ph.D., to its Board of Directors. Dolsten, who served as Pfizer’s chief scientific officer and president of research and development for 15 years, will support Immunai’s efforts ...

Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...

Pfizer has partnered with ... “We look forward to helping expedite research into novel therapeutics as our intelligent digital drug discovery and development platform continues to expand and ...

Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ ...

Pfizer is going "all in" to develop its ... as well as its disappointing internal research and development operations.

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study assessed vepdegestrant against AstraZeneca’s hormone med Faslodex in 624 ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE ... wide range of companies that provide patient care, research and development of new medicines, and design, manufacture ...

Research and development expenses for 2024 were $150. ... Bradley Canino, Stifel, inquired about the focus of the Pfizer ADC collaboration. Allen Yang explained the focus is broader, targeting ...

About Pfizer Oncology At Pfizer Oncology ... Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated ...

Pfizer has partnered with ... “We look forward to helping expedite research into novel therapeutics as our intelligent digital drug discovery and development platform continues to expand and ...